What they say: Introduction:
A recent study from the Department of Genetics, Paul F. Glenn Laboratories for the Biological Mechanisms of Aging Harvard Medical School, Boston,USA; and Department of Pharmacology, School of Medicine, The University of New South Wales, Australia shows that Sirtuin-2 induces the checkpoint kinase BubR1 to increase lifespan. This study was published, in the 1 July 2014 issue of the journal “EMBO”, by Prof Sinclair, North BJ, and others.
What we say:
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Lifespan extension therapy: Epidermal growth factor (EGF) may increase life span via up-regulation of its target gene BubR1
From research findings to Therapeutic Opportunity:
This study suggests, for the first time, that EGF, by increasing the expression of its target gene, it may: (a) increase the expression of BuBR1; and (b) regulate the expression of a number of longevity-promoting molecules (Fig. 1).
Thereby, it may: (1) increase insulin sensitivity; (2) attenuate cognitive impairment; (3) delay diseases of aging; (4) slow down cardiac aging; (5) promote resistance to bone, immune and motor dysfunction; (6) promote tissue rejuvenation; and (7) prolong median life span. Thus, pharmacological formulations encompassing “EGF or its activators, either alone or in combination with other drugs,“ may be used to extend the lifespan of an individual (fig. 2).
Details on the research findings:
Idea Proposed/Formulated (with experimental evidence) by:
Dr L Boominathan Ph.D.
Undisclosed mechanistic information: How EGF increases the expression of BubR1 and extends mammalian life-span
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
# Research cooperation
Citation: Boominathan, L., Lifespan extension therapy: Epidermal growth factor (EGF) may increase life span via up-regulation of its target gene BubR1, 14/June/2018, 11.10 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at firstname.lastname@example.org